Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

IDYABullishCorporate Developmentsnews

High materiality8/10

IDEAYA, Genentech Collaborate on PRMT5 KRAS G12D PDAC Therapy

Aug 19, 2026, 6:03 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Direct collaboration with Genentech and clear near-term development milestones create potential positive re-rating catalysts for IDEAYA; the addressable 15% PDAC subset adds optionality beyond IDEAYA's current programs.

AI summary

What happened, with direct paths to the underlying reporting

IDEAYA Biosciences and Genentech announced a clinical collaboration to evaluate IDE892 with Genentech's KRAS G12D inhibitor in MTAP-deleted KRAS G12D PDAC. Genentech sponsors the trial; IDEAYA supplies IDE892. The MTAP deletion/KRAS G12D co-occurrence (up to ~15% of PDAC) could unlock best-in-class PRMT5 combinations and near-term development catalysts.

IDEAYA and Genentech announce collaboration to evaluate IDE892 with GDC-7035 in MTAP-deleted PDAC.
Genentech sponsors the trial; IDEAYA supplies IDE892 with joint governance.
MTAP deletions co-occur with KRAS G12D in up to ~15% of PDAC patients.
2H 2026 plan to initiate IDE892 with RG6505 in MTAP-deleted, KRAS-mutant PDAC.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.